CD40L Antagonism in Rheumatoid Arthritis (RA)
| Condition | Rheumatoid Arthritis |
|---|---|
| Phase | Phase 2 |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Status | Terminated |
| Enrollment | 2 participants |
| Interventions | Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi |
| Start date | Jul 25, 2023 |
| Completion date | Jul 28, 2025 |
| Results posted | Jul 20, 2026 |
Summary
The primary objective is to determine if the addition of a 12-week course of treatment with VIB4920 to TNFi treatment will result in improved clinical disease control in patients with RA who have had an inadequate response to a TNFi.
Proportion of Participants Achieving Low Disease Activity by Simplified Disease Activity Index (SDAI)
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
- Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
- A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replace — Smith & Nephew, Inc.